- Home
- MTNB vs ACON Comparison
MTNB vs ACON Comparison
Compare MTNB & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | ACON |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MTNB | ACON |
|---|---|---|
| Price | $0.70 | $4.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 34.5K | ★ 2.4M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,483.00 |
| Revenue This Year | N/A | $71.77 |
| Revenue Next Year | N/A | $80.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.91 |
| 52 Week Low | $0.47 | $4.00 |
| 52 Week High | $3.09 | $984.09 |
Technical Indicators
Market Signals| Indicator | MTNB | ACON |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.61 |
| Support Level | N/A | $4.32 |
| Resistance Level | N/A | $9.36 |
| Average True Range (ATR) | 0.00 | 0.64 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 0.00 | 0.37 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.